menu
    • menu
    [{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Laboratorios Sophia \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Laboratorios Sophia \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Inapplicable"},{"orgOrder":0,"company":"Laboratorios Sophia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"MEXICO","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Laboratorios Sophia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Laboratorios Sophia \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Laboratorios Sophia \/ Inapplicable"},{"orgOrder":0,"company":"NTC","sponsor":"I-MED","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NTC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Ointment","sponsorNew":"NTC \/ I-MED","highestDevelopmentStatusID":"15","companyTruncated":"NTC \/ I-MED"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Wize Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Bonus BioGroup","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Ophthalmic Solution","sponsorNew":"Wize Pharma \/ Bonus BioGroup","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Bonus BioGroup"},{"orgOrder":0,"company":"Wize Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Wize Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Wize Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Wize Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fundaci\u00f3n Oftalmol\u00f3gica Los Andes","sponsor":"Alcon Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Fundaci\u00f3n Oftalmol\u00f3gica Los Andes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Fundaci\u00f3n Oftalmol\u00f3gica Los Andes \/ Alcon Inc","highestDevelopmentStatusID":"10","companyTruncated":"Fundaci\u00f3n Oftalmol\u00f3gica Los Andes \/ Alcon Inc"},{"orgOrder":0,"company":"Eximore","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Eximore","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eximore \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eximore \/ Inapplicable"},{"orgOrder":0,"company":"BIOSYENT PHARMA INC","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"BIOSYENT PHARMA INC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Suppository","sponsorNew":"BIOSYENT PHARMA INC \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BIOSYENT PHARMA INC \/ Undisclosed"},{"orgOrder":0,"company":"Bloomage Biotechnology Corp., Ltd","sponsor":"Lumenis","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Bloomage Biotechnology Corp., Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bloomage Biotechnology Corp., Ltd \/ Lumenis","highestDevelopmentStatusID":"15","companyTruncated":"Bloomage Biotechnology Corp., Ltd \/ Lumenis"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"||CD44","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Pre-Filled Injection","sponsorNew":"Anika Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"The Affiliated Hospital of Qingdao University | Nakhia Impex","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dove Medical Press \/ The Affiliated Hospital of Qingdao University | Nakhia Impex","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ The Affiliated Hospital of Qingdao University | Nakhia Impex"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Solution","sponsorNew":"Dove Medical Press \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ Inapplicable"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Neurology","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dove Medical Press \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ Inapplicable"},{"orgOrder":0,"company":"Nakhia Impex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Neurology","graph2":"Undisclosed","graph3":"Nakhia Impex","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nakhia Impex \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nakhia Impex \/ Inapplicable"},{"orgOrder":0,"company":"Dove Medical Press","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"CD44","graph1":"Dental and Oral Health","graph2":"Undisclosed","graph3":"Dove Medical Press","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dove Medical Press \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dove Medical Press \/ Inapplicable"},{"orgOrder":0,"company":"JGL d.d","sponsor":"Poseidon Clinical Research Balkans LLC","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sodium Hyaluronate","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase III","graph3":"JGL d.d","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"JGL d.d \/ Poseidon Clinical Research Balkans LLC","highestDevelopmentStatusID":"10","companyTruncated":"JGL d.d \/ Poseidon Clinical Research Balkans LLC"}]

    Find Clinical Drug Pipeline Developments & Deals for EUFLEXXA injection

    Menu

    EUFLEXXA injection

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bloomage Biotechnology Corp., Ltd

                            China
                            CPhI WW Frankfurt
                            Booth #11.1G6
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothBloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Lumenis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lumenis and Bloomage Biotech jointly released a new product - M22 medical wound dressing

                            Details : M22 medical wound dressing (sodium hyaluronate) is a versatile laser treatment system based on Lumenis' medical beauty concept of "30% Laser Treatment and 70% Postoperative care.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 03, 2023

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Lumenis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Bloomage Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            JGL d.d

                            Croatia arrow
                            CAMX
                            Not Confirmed

                            JGL d.d

                            Croatia arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Poseidon Clinical Research Balkans LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vizol S DIGI EYE Efficacy and Safety Study in Patients with Dry Eye

                            Details : Vizol S DIGI EYE is a drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Vizol S DIGI EYE

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 03, 2025

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Poseidon Clinical Research Balkans LLC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BIOSYENT PHARMA INC

                            Canada arrow
                            CAMX
                            Not Confirmed

                            BIOSYENT PHARMA INC

                            Canada arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement

                            Details : Under the agreement, BioSyent extended its agreement with its European partner for RepaGyn (sodium hyaluronate) and Proktis-M, extending its exclusive Canadian rights to these products until 2032.

                            Product Name : Repagyn

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 15, 2024

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dove Medical Press

                            Country arrow
                            CAMX
                            Not Confirmed

                            Dove Medical Press

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Local Injection of Periodontal Pocket Method for the Treatment of Gingivitis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 13, 2023

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dove Medical Press

                            Country arrow
                            CAMX
                            Not Confirmed

                            Dove Medical Press

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Injection Therapy for Neuropathic Pain

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 12, 2023

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nakhia Impex

                            Country arrow
                            CAMX
                            Not Confirmed

                            Nakhia Impex

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Local Injection for the Treatment of Chronic Wounds and Pain Caused by Chronic Wounds

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 12, 2023

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dove Medical Press

                            Country arrow
                            CAMX
                            Not Confirmed

                            Dove Medical Press

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Dental and Oral Health

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HA35 Treatment the Gingival Discomfort as Well as Gingival Redness and Bleeding of Patients With Periodontitis

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 13, 2023

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Dental and Oral Health

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Dove Medical Press

                            Country arrow
                            CAMX
                            Not Confirmed

                            Dove Medical Press

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Undisclosed

                            Sponsor : The Affiliated Hospital of Qingdao University | Nakhia Impex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study of Freshly Manufactured 35kDa Hyaluronan Fragment in the Treatment of Pain

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 06, 2023

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Undisclosed

                            Sponsor : The Affiliated Hospital of Qingdao University | Nakhia Impex

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eximore

                            Country arrow
                            CAMX
                            Not Confirmed

                            Eximore

                            Country arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients Wi...

                            Details : Undisclosed

                            Product Name : Hyabak

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 16, 2022

                            Lead Product(s) : Sodium Hyaluronate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Anika Therapeutics

                            U.S.A arrow
                            CAMX
                            Not Confirmed

                            Anika Therapeutics

                            U.S.A arrow
                            CAMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

                            Details : Cingal (sodium hyaluronate) combination product of cross-linked hyaluronic acid (HA) proven to provide long lasting pain relief through 6 months plus TH steroid to provide fast, short-term pain relief.

                            Product Name : Cingal

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 11, 2022

                            Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth